Seeking Alpha
30 Sept 2026, 23:42 UTC · 59m ago
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
Verdict
Headline takes no side. We score SGMT +0.50 — strongly bullish.
- Expected · SGMT
+0.50strongly bullish
−1 bearish0bullish +1More positive than 72% of ticker scores this week



